UNH Stock: UnitedHealth Crushed Earnings and Raised Guidance — Is the Crisis Over?

UnitedHealth Group (UNH) Q2 2026 — UnitedHealth Group (UNH), the largest U.S. health insurer, reported a blowout Q2 2026: adjusted EPS of $6.38 crushed the ~$4.94 estimate and jumped 56% from $4.08 a year ago, as the medical care ratio fell to 86.7% (from 89.4%) and operating profit rose 55% to $8.0B. Management RAISED full-year adjusted EPS guidance to $19.50–$20.00 and doubled buybacks to $5B+. The stock (~$427, up on the print) has nearly doubled off its $235 low and sits ~7% off its $462 recovery high. The catch: revenue was flat, membership is shrinking (down ~1.6M YoY), the beat was flattered by an $860M reserve release, and a DOJ Medicare probe lingers. A year ago UnitedHealth was in free-fall — guidance pulled, a CEO change, surging medical costs, a Justice Department probe — and the stock crashed from over $600 to near $235. Q2 2026 is the clearest sign yet the crisis is over: adjusted EPS of $6.38 crushed the ~$4.94 estimate (up 56% YoY), the all-important medical care ratio fell to 86.7% from 89.4%, operating profit rose 55% to $8.0B, and, unlike its peers, management RAISED full-year guidance to $19.50–$20.00 and doubled buybacks to at least $5B. This is a genuine, high-quality turnaround from the best franchise in healthcare. But we can't pound the table: revenue was essentially flat, membership is shrinking (down ~1.6M YoY as it walks away from unprofitable business), the beat was flattered by an $860M favorable reserve release, and the DOJ Medicare overhang lingers. It's a margin-recovery-on-shrinking-membership story, and the stock has already nearly doubled off its low to ~22x forward earnings. Our owner-earnings work lands fair value near $450 (vs ~$427), modest upside and a touch below the Street's ~$459. Our call: HOLD, 3/5 — a real recovery, roughly fairly valued after a huge run. Own it for the quality, add on real weakness, and watch the medical care ratio. Not financial advice. THE CALL: HOLD (3/5, A REAL TURNAROUND, NOW ROUGHLY FAIRLY PRICED — A QUALITY BEAT WITH AN ASTERISK) — base-case value ~$450 vs ~$427 today. What to watch: the medical care ratio continuing to fall on clean, reserve-free quarters — the proof the recovery is durable and not a one-off; the risk to respect is a flare-up in the DOJ Medicare probe or any walk-back of the raised guidance, either of which reopens the crisis narrative Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.